Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 11 May 2023 |
| Orion Corporation: Managers' transactions - Maziar Mike Doustdar | 8 May 2023 |
| Orion Corporation: Managers' transactions - Veli-Matti Mattila | 8 May 2023 |
| Orion Corporation: Managers' transactions - Karen Lykke Sørensen | 8 May 2023 |
| Orion Corporation: Managers' transactions - Kari Jussi Aho | 8 May 2023 |